HCA Healthcare CEO Samuel N. Hazen sells 42,877 shares for $21.5M, reducing stake by 72.8%
On 2026-02-03, Samuel N. Hazen, HCA Healthcare's CEO, executed 7 separate sales totaling 42,877 shares for $21,483,274.82 at a blended average price of $501.04, reducing his post-transaction holdings to 16,024 shares from 58,901 shares. This represents a 72.8% reduction in the CEO's personal stake at a time when HCA's stock trades near its 52-week highs ($513.76 current vs. $515.85 52-week high, -0.4%), suggesting the sale occurred during a strong valuation environment. The fundamentals backdrop shows HCA generated $19.2B in revenue and $1.6B in net income on an 8.7% annual growth trajectory, with the company trading at a P/E of 18.48 and market cap of $117.2B. The magnitude and structure of this divestiture—a substantial reduction in the CEO's ownership concentration—warrants examination of whether this reflects portfolio rebalancing, tax planning, or potential shifts in the CEO's strategic positioning.